Site Search

... – Last week, The Appropriations and Financial Affairs Committee voted to fund LD 1577  An Act to Require Health Insurance Coverage for Biomarker Testing.  This legislation, which passed both House and Senate chambers earlier this month with broad bipartisan support, would increase access to  biomarker testing  for Mainers who need it, ensuring they can receive the right treatment at the right time for their disease. The following can ...

... sent Senate Bill 273 to the Governor’s desk for signing. This legislation will ensure that more insurance plans in the Hoosier state cover biomarker testing, a game changer in the fight against cancer and an essential step in accessing precision medicine treatments.  “Biomarker testing has given me better, more effective treatment options, a better chance of surviving cancer and more time with my family,” said ...

... “To improve access to care for those who hear the words “you have cancer,” ACS CAN also calls on the legislature to increase access to biomarker testing, a game changer in the fight against cancer and an essential step in accessing precision medicine treatments by ensuring state-regulated health insurance, including Medicaid, covers appropriate biomarker testing for patients who could benefit. Dubbed ‘the right treatment at the right time,’ precision medicine has played a critical role ...

... February 22, 2024 – A new paper released today in the Journal of Clinical Oncology    finds that while incorporating pharmacogenomic (PGx) testing into cancer care can help improve patient outcomes, barriers to PGx testing, discovery, and implementation are impacting its adoption and ... from them.” ACS CAN is working to improve access to PGx testing through its state advocacy work to expand insurance coverage of comprehensive biomarker testing, which includes PGx testing. Biomarker testing is a critical step toward accessing precision medicine, including targeted therapies; however, not all patients who could benefit ...